原发性肝癌合并胆管内癌栓12例临床分析

目的探讨原发性肝癌继发胆管癌栓的临床特点和诊治要点。方法回顾性分析1990～2003年12例HCC伴癌栓的外科治疗情况。结果本组原发性肝癌合并胆管内癌栓的发生率为4．69％(12／256)．术前确诊牢为25％(3／12)．肝癌切除加胆管癌栓清除术8例,肝癌切除加肝外胆管切除．胆肠内引流1例．单纯胆总管切开取栓术3例。术后1年生存率66．7％(8／12)．3年生存率25％(3／12),其中1例生存已超过5年。结论原发性肝癌伴胆管内癌栓十分少见．术前易误诊．手术治疗不失为一种积极有效的治疗方法。     

原发性肝癌伴胆管癌栓的诊治

目的　探讨原发性肝癌伴胆管癌栓的诊治方法。方法　回顾性分析 8年间收治的 2 1例原发性肝癌伴胆管癌栓的临床资料。结果　临床表现为肝癌及梗阻性黄疸症状 ;术前正确诊断率76.2 %,B超 ,CT ,MRI ,ERCP和PTC的正确诊断率分别为 14 .3 %,9.5 %,14 . 3 %,71.4%和10 0 %。行肝癌切除加胆管癌栓清除术 10例 ,肝癌切除加肝外胆管切除术 5例 ,单纯胆总管切开取栓加肝动脉化疗栓塞 (TACE ) 3例 ,胆管癌栓清除加肝动脉灌注 (HIA ) 3例。术后 3年生存率 44 .4%,5年生存率 2 8.6%。结论　原发性肝癌伴胆道癌栓的诊断应选择多种检查手段 ,综合分析 ;以外科为主的综合治疗是积极有效的治疗方法。     

原发性肝癌伴胆管癌栓的外科治疗

目的探讨伴胆管癌栓的原发性肝癌(HCC)外科治疗方式的选择及对预后的影响。方法回顾性分析2000~2004年12例HCC伴胆管癌栓的外科治疗情况。结果所有12例患者中,术中死亡1例。发生胆道出血,经保守治疗而愈2例。平均存活时间为7个月,其中肿瘤切除组存活10~30个月,肿瘤未切除引流组术后存活4~10个月。结论原发性肝癌伴胆管癌栓行外科治疗是一种积极有效的治疗方法。     

原发性肝癌伴胆管癌栓的外科处理

目的 探讨原发性肝癌合并胆管癌栓的外科治疗及其疗效。方法 对浙江省台州市中心医院1995年1月至2007年10月收治的13例原发性肝癌合并胆管癌栓的治疗情况进行回顾性总结和分析。结果 肝癌切除加胆管癌栓清除术10例,单纯胆管切开取栓术3例。7例获得随访,3例1年内死亡,3例存活1到4年,1例至今存活6年。结论 原发性肝癌伴胆管癌栓行外科治疗是一种积极有效的治疗方法。     

原发性肝癌伴门静脉癌栓的治疗方式探讨

目的　探讨原发性肝癌 (HCC)伴门静脉癌栓 (TTPV )的有效治疗方式。方法　回顾性分析和总结 1995年 1月至 2 0 0 3年 5月期间收治的 95例原发性肝癌伴门静脉癌栓患者的临床资料。结果　 5 8例行手术治疗 ,其中 6例行单纯肝肿瘤切除术 ,1、3年生存率为 3 3 .3 %、0 % ;5 2例行肝肿瘤切除加门静脉癌栓取栓术 ,其中 43例术后采用了肝动脉和门静脉双插管微量泵灌注化疗 ,其 1、3、5年生存率为 10 0 %、5 5 .8%、13 .9% ,9例未行插管化疗 ,1、3、5年生存率为 77.7%、2 2 .2 %、0 %。另 3 7例未行手术者中 10例行单纯肝动脉栓塞 (HAE) ,1、3年生存率为 2 0 %、0 % ;2 1例行选择性门静脉栓塞 (SEPV)联合肝动脉栓塞 ,1、3、5年生存率为 71.4%、2 8.6%、9.5 % ;6例未作任何治疗者均 1年内死亡。结论　手术治疗原发性肝癌伴门静脉癌栓有效 ,术后使用肝动脉和门静脉双插管灌注化疗可提高疗效 ,选择性门静脉栓塞联合肝动脉栓塞对不能切除的肝癌伴门静脉癌栓有重要作用     

原发性肝癌合并门静脉癌栓的外科治疗方式选择

目的探讨原发性肝癌(HCC)合并门静脉癌栓(TTPV)的外科治疗方式选择。方法对1990年1月至2003年1月期间收治的138例肝癌合并门静脉癌栓患者的临床资料进行分析和总结。结果37例行保守姑息治疗患者1至8个月内死亡,平均生存时间3．9个月。101例患者行手术治疗,其中23例行单纯肝癌切除术,平均生存时问10．9个月;78例采取各种手术方式行肝癌切除加门静脉癌栓取栓术,平均生存时间26．8个月。其中52例术后采用了肝动脉和门静脉双插管微量泵灌注化疗,其1、3、5年生存率为96．2％、51．9％、11．5％,26例未行插管化疗,1、3、5年生存率为76．9％、23．1％、0％。结论手术治疗比保守治疗能相对延长肝癌合并门静脉癌栓患者的生存时间;手术在切除肝癌的同时应尽量使用各种方式取出门静脉癌栓;术后使用肝动脉和门静脉双插管微量泵灌注化疗可有效提高治疗效果。     

原发性肝癌伴胆管癌栓11例的治疗体会

目的 原发性肝癌伴胆管癌栓的外科手术治疗及其治疗效果。方法 回顾性总结原发性肝癌伴胆管癌栓１１例行胆管切开癌栓清除术,其中加做肝癌局部切除术７例。结果 手术死亡２例,术后随访１年,除１例至今仍存活１１个月外,余８例生存期分别为１１,１０,９,８．５,４．５,３,３个月。平均生存时间为６个月。结论肝癌局部切除加胆管切开癌栓清除术术不失为原发性肝癌伴胆管癌栓患者的一种姑息治疗方法。     

原发性肝癌的手术治疗：附408例分析

目的　探讨原发性肝癌的手术治疗效果及影响疗效的因素。方法　回顾性分析近 8年外科手术治疗的原发性肝癌 40 8例患者的临床资料。结果　 40 8例占同期原发性肝癌住院之 43 .9% ,大肝癌占 81.9% ,伴门静脉癌栓者占 8.5 % ,伴胆管癌栓者 4.8%。 40 8例中行左外叶切除 118例 ,左半肝切除 97例 ,右半肝切除 112例 ,右肝肿瘤所在区段切除 73例 ,左、右叶肿瘤同时切除 8例。同时行门静脉癌栓 (左、右支或主支 )取栓术 3 5例 ,同时行肝内外胆管癌栓取栓术 2 0例 ;加行全植入或药泵置入 (DDS) 48例 (3 5例有门静脉癌栓者均经门静脉置入 )。术后发生并发症共 3 0 2例次。包括膈下脓肿、肺部感染 ,上消化道出血 ,胸腔积液、腹水、伤口裂开等。手术死亡率 2 .7% ,残癌率为18.4% ,术后复发或转移率为 73 .0 %。 1,3 ,5年生存率分别为 73 .9% ,5 1.3 % ,3 5 .5 %。结论　原发性肝癌接受手术治疗者的病期均较晚 ,术后复发和 /或转移是影响远期疗效的主要因素。     

肝细胞性肝癌合并门静脉癌栓63例临床治疗分析

目的:比较不同治疗方法对肝细胞性肝癌(HCC)合并门静脉癌栓(PVTT)的疗效及其意义。方法:回顾性分析应用不同治疗方式治疗的63例原发性HCC合并门静脉主干或者第一分支癌栓患者的预后。按照治疗方式的不同分为4组:保守治疗组(A组,7例);TACE治疗组(B组,19例);手术切除原发HCC同时行门静脉切开取栓术或者癌栓部位门静脉切除术治疗组(C组,12例);手术切除原发HCC同时行门静脉切开取栓术或者癌栓部位门静脉切除术+术后TACE治疗组(D组,25例)。结果:A组中位生存期为2个月,半年、1年、2年、3年生存率分别为14%、0、0、0;B组中位生存期为6个月,半年、1年、2年、3年生存率分别为56%、12%、0、0;C组中位生存期为10个月,半年、1年、2年、3年生存率分别为、74%、37%、9%、0;D组中位生存期为16个月,半年、1年、2年、3年生存率分别为80%、52%、20、12%。各组生存率比较差异均具有统计学意义(P<0.05)。结论:原发性HCC合并PVTT采取手术切除原发肝癌同时行门静脉切开取栓术或者癌栓部位门静脉切除术可明显延长生存期,术后应用TACE治疗可进一步延长生存期,提高生存率。     

原发性肝癌伴胆管癌栓致阻塞性黄疸的外科治疗

目的探讨原发性肝癌伴胆管癌栓致阻塞性黄疸的外科手术治疗及其治疗效果。方法回顾性对15例原发性肝癌伴胆管癌栓致阻塞性黄疸行外科手术治疗的总结和分析。结果行左半肝切除 胆总管切开取癌栓术5例,行肿瘤切除 胆总管切开取癌栓术7例,行胆总管切开取癌栓 肝总动脉结扎3例,术后随访2年,平均生存时间为14.5个月,最长存活23个月。结论外科治疗明显提高了患者生活质量,延长了生存时间。     

Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi

BACKGROUND: The aim of this study was to evaluate the clinicopathologic characteristics of patients with hepatocellular carcinoma (HCC) and bile duct thrombi (BDT). PATIENTS: Seventeen patients with HCC and BDT among 671 patients with HCC who underwent hepatic resection were enrolled in this study. RESULTS: There were no significant differences in the survival rates between patients with and those without BDT, although the rate of stage IV or portal vein invasion was significantly higher in patients with HCC and BDT than in those with HCC but without BDT. In 9 of 17 patients with BDT, preoperative jaundice was observed. Five of the 17 patients underwent a bile duct resection combined with hepatic resection, and 12 patients underwent hepatic resection with removal of the BDT without bile duct resection. None of the patients had histopathologic evidence of direct tumor invasion into the bile duct wall or of any tumor recurrence related to the BDT. There were no significant differences in the survival rates between patients who underwent bile duct resection and those who did not. CONCLUSION: Hepatic resection and the removal of BDT without bile duct resection were sufficient surgical interventions to treat patients with HCC and BDT.     

ԭ���Ըΰ��鵨�ܰ�˨����ƴ���

??Surgical intervention of primary hepatic carcinoma with bile duct thrombi YANG Xiao-Ping*, BO Jian-Guo, CAI Xiu-Jun.*Department of General Surgery, Zhejiang Taizhou Central Hospital ,Taizhou 318000 ,China Abstact Objective To study the surgical intervention of primary hepatic carcinoma (PHC) with bile duct thrombi (BDT). Methods Restrospective study was performed on the treatment of 13 cases of PHC with bile duct thrombi from 1995 to 2007.??Results The operative procedures included hepatectomy with removal of BDT (n=10),thrombectomy through bile duct (n=3). 7 patients were followed up, 3 patients were died in one year , 3 patients were survived in 1~4 years, one patients was survived over 6 years. Conclusion Surgical intervention was effective for patients with PHC and BDT.     

肝癌伴胆管癌栓的临床病理及预后分析

目的 探讨肝癌伴胆管癌栓的临床病例特点对预后的影响.方法 回顾性分析了1995-2005年21例肝癌伴胆管癌栓的ll缶床病例特点与预后情况.结果 该组HCC伴胆管癌栓病人的1年生存率为66.7%,3年生存率为42.9%,中位生存时间为29.5个月.有无癌栓侵犯胆管壁的两组病例生存率差异无显著意义(P>0.05),癌栓位置不同生存率无差别(P>0.05).结论 对于HCC伴胆管癌栓病例,胆管壁受侵犯和胆管内癌栓的位置不影响预后.     

Surgical Intervention for Obstructive Jaundice Due to Biliary Tumor Thrombus in Hepatocellular Carcinoma

This retrospective study in eight surgically treated patients with obstructive jaundice due to biliary tumor thrombus in a patient with hepatocellular carcinoma (HCC) was performed to evaluate the role of surgical intervention. All biliary tumor thrombi were confirmed preoperatively or intraoperatively. Only two manifested intraluminal biliary obstructions due to a primary tumor that had not been found preoperatively. The operative procedures included hepatectomy with removal of the biliary tumor thrombus (n = 3), hepatectomy combined with extrahepatic bile duct resection (n = 1), thrombectomy through a choledochotomy (n = 3), and piggyback orthotopic liver transplantation (n = 1). The 1- and 3-year survival rates were 62.5% and 37.5%, respectively. Two patients survived more than 5 years. Surgical intervention was effective in patients with obstructive jaundice due to a biliary tumor thrombus in an HCC. Thus surgery for a recurrence can prolong survival, and liver transplantation is a treatment worthy of further investigation.     

原发性肝细胞癌合并胆管癌栓的外科诊治分析

目的探讨原发性肝细胞癌合并胆管癌栓的诊断及外科治疗效果。方法回顾性总结和分析20例原发性肝细胞癌合并胆管癌栓的外科诊治情况。采用肝叶切除及癌栓取出术7例、单纯胆管癌栓取出3例;肝动脉化疗栓塞术(transcatheter hepatic arterial chemoembolization,TACE)后肝切除加癌栓取出术10例。术后均行胆管引流及TACE。结果术前行TACE的10例患者,术中胆道出血(45.2±12.5)ml,明显少于未行TACE者(90.5±10.5)ml,差异显著(P0.05)。全部病例均获随访,平均时间22(2～54)个月。肝叶切除及癌栓取出7例,平均生存(21.5±2.8)个月;术前TACE、2周后行肝叶切除加癌栓取出10例,平均生存(28.5±3.1)个月;单纯癌栓取出3例,平均生存(4.1±0.5)个月,术前行TACE组生存时间明显长于其余两组(P0.05)。结论对原发性肝细胞癌合并胆管癌栓早期诊断、积极切除肿瘤并清除胆管癌栓,配合术前术后TACE术,是改善预后的有效治疗方法。     

Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience

From 1977 to 1997, surgical resection was possible in 142 (80%) of 177 patients with hilar cholangiocarcinoma after relieving jaundice by single or multiple percutaneous transhepatic biliary drainage followed by percutaneous transhepatic cholangioscopy and/or percutaneous trans-hepatic portal vein embolization. Curative resection was possible in 108 (61%) of the 142 patients, and 100 of these patients underwent various types of hepatectomy with caudate lobectomy for a 30-day operative mortality rate of 6% and 9% hospital mortality. Combined portal vein resection was carried out in 43 cases including 41 hepatectomies and 2 bile duct resections. Hepatopancreatoduodenectomy was performed in 16 patients. Cancer recurrence was observed in 58 of the 108 patients undergoing curative resection. The 3-, 5-, and 10-year survival rates for 100 patients undergoing curative hepatectomy and 8 with curative bile duct resection were 43%, 26%, and 19%; and 31%, 16%, and 0%, respectively; those for 40 patients with positive lymph node metastasis, 84 with perineural invasion, and 43 with combined portal vein resection were 27%, 14%, and 7%; 34%, 21%, and 13%; and 18%, 6%, and 0%, respectively. These survival rates are significantly better than those for 35 patients with unresectable cancer. Curative resection after aggressive preoperative management is recommended as a reasonable surgical approach to hilar cholangiocarcinoma. Received for publication on Aug. 23, 1999; accepted on Nov. 29, 1999     

肝细胞癌合并门静脉癌栓的外科治疗

目的探讨肝细胞癌伴门静脉癌栓的外科治疗方法。方法回顾性分析我院2000年1月～2006年12月收治的肝细胞癌合并门静脉癌栓63例的临床资料。根据治疗方式的不同分为综合治疗组(21例)、门静脉取栓组(12例)和姑息治疗组(30例),比较各组的生存期。结果综合治疗组、门静脉取栓组和姑息治疗组的中位生存时间分别为12.7个月、7.4个月和4.3个月,有显著性差异(P<0.05)。综合治疗组、门静脉取栓组的疗效均明显优于姑息治疗组。结论对于能耐受手术的门静脉癌栓病人应积极行肝癌切除术并术中取栓治疗。